Immuneering (IMRX) Aktievy
Immuneering Corporation, ett onkologiföretag i sen fas, utvecklar läkemedel för breda grupper av cancerpatienter i USA. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 2/6 |
| Framtida tillväxt | 2/6 |
| Tidigare resultat | 0/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 0/6 |
Belöningar
Riskanalys
+ 1 större risk
IMRX Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Immuneering Corporation Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$5.06 |
| 52 veckors högsta | US$10.08 |
| 52 veckors lägsta | US$3.25 |
| Beta | 0.37 |
| 1 månads förändring | 9.05% |
| 3 månaders förändring | 3.90% |
| 1 års förändring | 34.57% |
| 3 års förändring | -43.53% |
| 5 års förändring | -83.37% |
| Förändring sedan börsintroduktionen | -71.23% |
Senaste nyheter och uppdateringar
Immuneering: A Third (Much Cheaper) Way To Invest In The RAS-RAF-MEK-ERK 'Revolution'
Summary Immuneering Corporation targets first-line pancreatic cancer with atebimetinib, showing promising Phase 2a results versus standard-of-care regimens. IMRX's pivotal Phase 3 trial in first-line PDAC is recruiting, with first patient dosing expected mid-2026 and cash runway projected into 2029. Atebimetinib demonstrated median overall survival of 17.3 months, outperforming historical controls and comparing favorably to competitors’ data. Despite strong clinical data and differentiated tolerability, IMRX trades at a deep discount to peers, presenting a high-risk, high-reward opportunity. Read the full article on Seeking AlphaCompanies Like Immuneering (NASDAQ:IMRX) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...Recent updates
Immuneering: A Third (Much Cheaper) Way To Invest In The RAS-RAF-MEK-ERK 'Revolution'
Summary Immuneering Corporation targets first-line pancreatic cancer with atebimetinib, showing promising Phase 2a results versus standard-of-care regimens. IMRX's pivotal Phase 3 trial in first-line PDAC is recruiting, with first patient dosing expected mid-2026 and cash runway projected into 2029. Atebimetinib demonstrated median overall survival of 17.3 months, outperforming historical controls and comparing favorably to competitors’ data. Despite strong clinical data and differentiated tolerability, IMRX trades at a deep discount to peers, presenting a high-risk, high-reward opportunity. Read the full article on Seeking AlphaCompanies Like Immuneering (NASDAQ:IMRX) Are In A Position To Invest In Growth
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Pancreatic Cancer Breakthrough And Long Patent Tail Will Transform This Oncology Platform
Catalysts About Immuneering Immuneering is a biotechnology company focused on developing atebimetinib, a MEK inhibitor, for cancers driven by the MAP kinase pathway, with an initial focus on first line pancreatic cancer and expansion into lung cancer and other tumor types. What are the underlying business or industry changes driving this perspective?
Pivotal Pancreatic Cancer Trial And Extended Patent Protection Will Shape A Long Runway
Catalysts About Immuneering Immuneering is a clinical stage biotech company focused on developing atebimetinib, a MEK inhibitor, for cancers driven by the MAP kinase pathway, with an initial focus on first line pancreatic cancer and expansion into lung cancer. What are the underlying business or industry changes driving this perspective?Companies Like Immuneering (NASDAQ:IMRX) Are In A Position To Invest In Growth
Just because a business does not make any money, does not mean that the stock will go down. Indeed, Immuneering...Here's Why Immuneering (NASDAQ:IMRX) Must Use Its Cash Wisely
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Immuneering (NASDAQ:IMRX) Will Have To Spend Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Companies Like Immuneering (NASDAQ:IMRX) Could Be Quite Risky
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Is Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...Immuneering: Phase 1 Data Release IMM-1-104 Leads To Additional 2024 Milestone
Summary Positive safety and anti-tumor activity released from phase 1 portion of phase 1/2a study, using IMM-1-104 for the treatment of patients with RAS-mutant solid tumors. Additional expansion cohort results from the phase 2 portion of the phase 1/2a study, using IMM-1-104 for the treatment of patients with RAS-mutant solid tumors, expected later in 2024. IMM-6-415 is another MAPK pathway targeting drug, but is able to target either RAS or RAF solid tumors; Dosing of first patient in phase 1 study expected in March 2024. Immuneering had $85.7 million in cash as of December 31st of 2023; Enough cash to fund its operations into the 2nd half of 2025. Read the full article on Seeking AlphaIs Immuneering (NASDAQ:IMRX) In A Good Position To Deliver On Growth Plans?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...We're Not Very Worried About Immuneering's (NASDAQ:IMRX) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Immuneering wins FDA nod to study lead asset in solid tumors
The development-stage biotech Immuneering Corporation (NASDAQ:IMRX) announced Friday that the FDA greenlighted its Investigational New Drug (IND) application to study IMM-1-104, its lead candidate targeted at advanced RAS mutant solid tumors. Accordingly, the company expects to begin a Phase 1/2a clinical trial to assess the oral, once-daily therapy in advanced RAS mutant solid tumors across five clinical sites in the U.S. IMRX expects to follow the Phase 1 segment of the study with a dose expansion Phase 2a portion targeted at RAS mutated pancreatic, melanoma, colorectal, and lung cancers. The first patient is expected to enroll in Q4 2022. “Clearance of the IND for IMM-1-104 brings us one step closer to our goal of developing medicines with the potential to benefit every cancer patient with a RAS mutant solid tumor, not just those harboring specific mutations,” Chief Executive Ben Zeskind said. The announcement of the IND submission for IMM-1-104 sent IMRX shares higher early this month.Immuneering seeks FDA nod to conduct clinical trial for lead cancer candidate
The shares of development-stage biotech Immuneering Corporation (NASDAQ:IMRX) added ~9% in the pre-market trading Friday after the company announced the filing of an Investigational New Drug (IND) seeking FDA clearance to conduct a clinical trial for its lead asset IMM-1-104. An oral once-daily small molecule, IMM-1-104, targets advanced solid tumors with RAS mutations, unlike the candidates that target specific cancer mutations such as KRAS-G12C. “The preclinical data package for IMM-1-104 is uniquely compelling, and we are excited to now evaluate this compound in patients who so urgently need new options,” the Chief Executive of IMRX, Brett Hall, noted. With the IND submission, the FDA will review the company’s application to determine if the data support the safety of IMM-1-104. IMRX plans to conduct a Phase 1/2a clinical trial of IMM-1-104 across five internationally recognized clinical sites in the U.S. Amgen (AMGN) and Mirati Therapeutics (MRTX) are among the developers of cancer therapies targeted at KRAS G12C mutations.Immuneering initiated a Buy by Chardan, PT set to $18
Immuneering (NASDAQ:IMRX) initiated with a Buy by Chardan analyst Geulah Livshits and gave $18 as price target. The analyst likes the potential of Immuneering's pipeline and translational bioinformatics platform to address unmet needs in diverse cancers. The company's approach integrates analysis of high-throughput transcriptional, genomics, and proteomics datasets to generate insights into tumor signaling dynamics, and mechanisms of therapy response or resistance, to advance drug candidates with optimal signaling profiles, Livshits tells investors in a research note. Currently, the stock is trading at $6.3, a rise of ~10.7% on Friday. Stock has slumped about 64% over the last one year and company has a market cap of $139M . The stock is given a Wall Street 'Strong Buy' rating with 4.5 score (4 Strong Buy, 1 Buy, 1 Hold) Comparative rating of the stock against the peers:Aktieägarnas avkastning
| IMRX | US Biotechs | US Marknad | |
|---|---|---|---|
| 7D | 12.2% | 0.5% | 0.6% |
| 1Y | 34.6% | 35.8% | 20.1% |
Avkastning vs industri: IMRX presterade sämre än US Biotechs branschen som gav 35.8 % under det senaste året.
Avkastning vs Marknaden: IMRX översteg US marknaden som gav 20.1 % under det senaste året.
Prisvolatilitet
| IMRX volatility | |
|---|---|
| IMRX Average Weekly Movement | 11.2% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stabil aktiekurs: IMRX s aktiekurs har varit volatil under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: IMRX s veckovolatilitet ( 11% ) har varit stabil under det senaste året, men är fortfarande högre än 75 % av US aktier.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 2008 | 57 | Ben Zeskind | immuneering.com |
Immuneering Corporation, ett onkologiföretag i sen fas, utvecklar läkemedel för breda grupper av cancerpatienter i USA. Bolaget utvecklar IMM-1-104 (atebimetinib), en dubbel-MEK-hämmare som befinner sig i en klinisk fas 3-studie för behandling av patienter med cancer, inklusive bukspottkörtelcancer och icke-småcellig lungcancer orsakad av mutationer i RAS eller RAF; IMM-6-415 (envometinib), som befinner sig i en klinisk fas 1/2a-studie för behandling av patienter med solida tumörer; och flera program för upptäckt av djupcykliska hämmare. Bolaget har kliniska leveransavtal med Regeneron Pharmaceuticals för att utvärdera atebimetinib i kombination med Libtayo hos patienter med icke-resektabel eller metastaserande RAS-mutant icke-småcellig lungcancer; och med Eli Lilly and Company för att utvärdera atebimetinib i kombination med olomorasib hos patienter med avancerad eller metastaserande KRAS G12C-mutant icke-småcellig lungcancer.
Immuneering Corporation Sammanfattning av grunderna
| IMRX grundläggande statistik | |
|---|---|
| Börsvärde | US$327.37m |
| Vinst(TTM) | -US$57.28m |
| Intäkter(TTM) | n/a |
Är IMRX övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| IMRX resultaträkning (TTM) | |
|---|---|
| Intäkter | US$0 |
| Kostnad för intäkter | US$0 |
| Bruttovinst | US$0 |
| Övriga kostnader | US$57.28m |
| Intäkter | -US$57.28m |
Senast redovisade vinst
Jun 30, 2026
Nästa vinstdatum
n/a
| Vinst per aktie (EPS) | -0.89 |
| Bruttomarginal | 0.00% |
| Nettovinstmarginal | 0.00% |
| Skuld/egenkapitalförhållande | 0% |
Hur har IMRX utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/08/16 02:14 |
| Aktiekurs vid dagens slut | 2026/08/14 00:00 |
| Intäkter | 2026/06/30 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som används för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och handledningar på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Immuneering Corporation bevakas av 11 analytiker. 8 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Li Wang Watsek | Cantor Fitzgerald & Co. |
| Yevgeniya Livshits | Chardan Capital Markets, LLC |
| Andres Maldonado | H.C. Wainwright & Co. |